An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

PHASE4

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early due to challenges in recruitment. The decision to terminate the study was not related to any safety issues or concerns.

Conditions

Asthma

Interventions

DRUG: Reslizumab
DRUG: Fludeoxyglucose F 18 (FDG)
DRUG: Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.